Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom
NCT ID: NCT06276517
Last Updated: 2024-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
80 participants
OBSERVATIONAL
2024-03-31
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence, Characteristics and Evolution of Cerebral Vasospasm With Clinical Impact in Moderate to Severe Traumatic Brain Injury Complicated by Subarachnoid Hemorrhage at Martinique University Hospital
NCT06560372
Cerebrospinal Fluid Hemoglobin to Monitor for Aneurysmal Subarachnoid Hemorrhage Related Secondary Brain Injury
NCT04998370
Neurological Outcome in Patients of Traumatic Subarachnoid Haemorrhage
NCT02073890
Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage
NCT02915380
Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
NCT02326571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Progress over the past thirty years has led to a 57% reduction in mortality, but these figures do not always reflect the day-to-day reality of these patients, for whom recovery remains incomplete in almost half of cases. For example, a third of patients have not returned to work at one year, and of those who have, only half have returned to work full-time. In 2020, a Norwegian team showed that, at one year, a third of patients suffer from a "post-HSA syndrome", as yet little described, but which seems very similar to the post-concussion syndrome experienced by patients after head trauma. In their study, only 3% of patients with this syndrome returned to work at one year. A better understanding of the incidence of this syndrome, as well as its evolution and determinants, is therefore essential.
With this in mind, the investigators chose to assess the presence of post-SAH syndrome at 3 months and its repercussions on return to work, using the Rivermead questionnaire.
Secondly, in view of the prevalence of post-traumatic stress syndrome at 3 years (a quarter of patients), the investigators wished to study the factors determining the presence of post-HSA syndrome and an inability to return to work at 3 months, 6 months, 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with subarachnoid hemorrhage
Patients hospitalized in Lariboisière intensive care unit for subarachnoid hemorrhage
questionnaire
self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
SS-QoL
49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
SF-36
multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
CIQ-R
16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
BREFF
rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
MoCA
MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
IADL
8 questions rated from 0 to 1 to assess functional outcome
mMRS
mMRS score from 0 to 4 to assess functional outcome
PCL-5
To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
Brief-Cope
28-question self-questionnaires to study patients' coping strategies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
questionnaire
self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
SS-QoL
49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
SF-36
multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
CIQ-R
16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
BREFF
rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
MoCA
MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
IADL
8 questions rated from 0 to 1 to assess functional outcome
mMRS
mMRS score from 0 to 4 to assess functional outcome
PCL-5
To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
Brief-Cope
28-question self-questionnaires to study patients' coping strategies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient hospitalized in intensive care unit at Hôpital Lariboisière between September 2022 and September 2023 for subarachnoid hemorrhage due to aneurysmal rupture.
* Patient affiliated to the French social security system
* Patient expressing no objection
Exclusion Criteria
* Hospitalization \> 1 month
* Patient does not speak French
* Patient with diagnosis of neurodegenerative disease.
* Traumatic meningeal hemorrhage
* Patients on AME
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01739-34
Identifier Type: OTHER
Identifier Source: secondary_id
APHP220918
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.